GeLiPthin-1

SERVING SIZE: 3 capsules | SERVINGS PER CONTAINER: 40

VITAMINS & MINERALS: Zinc (as zinc picolinate) 7.5 mg (68.2% DV) — supports metabolic enzyme function and insulin signalling. Vitamin B6 (as pyridoxine HCl) 4.5 mg (264.7% DV) — cofactor for neurotransmitter synthesis including serotonin (appetite regulation). Chromium (as chromium picolinate) 180 µg (514.3% DV) — contributes to normal macronutrient metabolism; EU-authorised health claim for maintenance of normal blood glucose levels.

MULTI-PATH SATIETY BLEND (1,200 mg): Micronized Berberine Hydrochloride — alkaloid with published evidence on AMPK activation and glucose metabolism. Oleoylethanolamide (OEA) — endogenous lipid mediator that activates PPARα receptors in the gut, signalling satiety to the brain via the vagus nerve. Micronized Ginger root extract — traditional digestive support; published evidence on gastric motility and nausea reduction. Kutki (Picrorhiza kurroa) root extract — Ayurvedic hepatoprotective; supports bile flow and lipid metabolism. Micronized Gentiana Lutea root extract — bitter compound that stimulates GLP-1 secretion from L-cells in the gut. Hop Cone extract — contains isohumulones with published evidence on metabolic support. Micronized Curcumin — anti-inflammatory support via NF-κB pathway modulation; enhanced by Micro Matrix micronization. Micronized Saffron extract — published RCTs showing support for appetite regulation and mood via serotonergic pathways. Peppermint leaf extract — supports digestive comfort and gastric relaxation.

MICROBIOME AND GUT BLEND (336 mg): Deglycyrrhizinated Licorice (DGL, Glycyrrhiza glabra) root extract — mucosal barrier support without mineralocorticoid effects. Sodium Alginate — forms a protective raft in the stomach; supports gastric comfort and delayed gastric emptying (mechanical satiety signal). Calcium Carbonate — alkaline buffer supporting gastric pH balance. HPMC (Hydroxypropyl Methylcellulose) — matrix-forming polymer supporting controlled release. Bifidobacterium breve BBr60 (≥5 Billion CFU) — probiotic strain with published evidence on gut-brain axis signalling, appetite hormone modulation, and microbiome diversity.

THERMO-METABOLIC CATALYST BLEND (128.46 mg): EGCG from Green Tea extract — catechin with extensive published evidence on thermogenesis (121–176 kCal/day additional expenditure in meta-analyses) and fat oxidation via norepinephrine pathway. Micronised Capsicum — capsaicin source; activates TRPV1 receptors triggering thermogenic response. Micronised Capsiate — non-pungent capsaicin analogue providing thermogenic benefit without GI irritation. Micronised Piperine — bioavailability enhancer (inhibits glucuronidation); also activates TRPV1.

THE PROBLEM: Many of GeLiPthin-1's key actives (berberine, curcumin, saffron, ginger, capsicum) have notoriously poor oral bioavailability due to low water solubility, rapid first-pass metabolism, or degradation in gastric acid. Standard formulations deliver a fraction of the labelled dose to the bloodstream.

THE MICRO MATRIX SOLUTION: Each micronized ingredient in GeLiPthin-1 is embedded inside a precision-engineered matrix designed to support stability, absorption, and biological activity. The proprietary micronized micro-network: (1) Reduces particle size to ultra-fine dimensions for dramatically increased surface area and dissolution rate. (2) Encapsulates actives inside a supportive matrix that protects against stomach acid degradation. (3) Controls release so ingredients enter the bloodstream steadily — not all at once. (4) Enhances absorption at the intestinal epithelium where biological activity begins.

SPECIFIC APPLICATIONS IN THIS FORMULA: Micronized Berberine — standard berberine has ~5% oral bioavailability due to P-glycoprotein efflux and first-pass metabolism; micronization increases surface area and dissolution rate. Micronized Curcumin — uses the same NovoCurmin™ technology achieving 89 mg/mL water solubility (vs ~1-2 mg/mL standard). Micronized Saffron — protects delicate crocin and safranal compounds from oxidative degradation. Micronized Ginger — standardized gingerol content with enhanced dissolution. Micronized Capsicum/Capsiate — controlled-release micronization prevents GI irritation while maintaining thermogenic activity.

CONTROLLED-RELEASE ARCHITECTURE: The sodium alginate + HPMC matrix in the Microbiome & Gut Blend creates a physical gastric raft that (a) provides mechanical satiety signalling via stomach distension, (b) delays gastric emptying to prolong satiety, and (c) creates a controlled-release environment for the probiotic strain. This is pharmaceutical-grade matrix engineering applied to nutritional delivery.

Key takeaway: Micro Matrix Technology is not a marketing label — it is the core reason GeLiPthin-1 can deliver meaningful doses of poorly-bioavailable botanicals at the intestinal level where their biological targets (AMPK, PPARα, GLP-1 L-cells, TRPV1 receptors) are located.

PATHWAY 1 — APPETITE CONTROL & SATIETY SIGNALLING: Oleoylethanolamide (OEA) activates PPARα receptors in the small intestine, triggering vagal afferent signalling to the hypothalamus that produces a sensation of fullness. Gentiana Lutea bitter compounds stimulate GLP-1 secretion from intestinal L-cells — the same incretin hormone targeted by GLP-1 receptor agonist drugs (though via a different, indirect mechanism). Saffron extract (crocin/safranal) has published RCT evidence showing reduced snacking frequency via serotonergic appetite modulation. Berberine activates AMPK, which downstream influences appetite-regulating hormones.

PATHWAY 2 — THERMOGENESIS & ENERGY EXPENDITURE: EGCG inhibits catechol-O-methyltransferase (COMT), prolonging norepinephrine activity and increasing basal metabolic rate. Published meta-analyses show 121–176 kCal/day additional expenditure. Capsaicin and Capsiate activate TRPV1 (transient receptor potential vanilloid 1) channels, triggering sympathetic nervous system-mediated thermogenesis. Piperine enhances bioavailability of co-administered compounds while independently activating TRPV1. Combined thermogenic effect is additive across multiple receptor pathways.

PATHWAY 3 — METABOLIC SUPPORT & GLUCOSE REGULATION: Berberine HCl has extensive published evidence on AMPK activation — the same 'metabolic master switch' activated by metformin. Published human studies show support for healthy glucose metabolism and lipid profiles. Chromium picolinate (180 µg) has EU-authorised health claim for contribution to maintenance of normal blood glucose levels. Curcumin supports healthy inflammatory response via NF-κB modulation — chronic low-grade inflammation is associated with metabolic dysfunction. Hop cone isohumulones have published evidence on metabolic support pathways.

PATHWAY 4 — GUT-BRAIN AXIS & MICROBIOME: Bifidobacterium breve BBr60 (≥5 Billion CFU) modulates gut-brain axis signalling. Published evidence shows B. breve strains influence appetite hormones (ghrelin, PYY) and support microbiome diversity associated with healthy body composition. Sodium alginate forms a physical gastric raft providing mechanical satiety via stomach distension and delayed gastric emptying. DGL (Deglycyrrhizinated Licorice) supports mucosal barrier integrity — a healthy gut lining is essential for proper nutrient sensing and hormone signalling. The delayed-release matrix ensures probiotic viability through gastric transit.

SYNERGISTIC DESIGN: These four pathways are not redundant — they target different physiological timescales. Thermogenesis provides immediate metabolic boost. Satiety signalling reduces caloric intake within hours. Metabolic support improves glucose handling over days-weeks. Microbiome remodelling creates lasting changes over weeks-months. This multi-timescale approach is the core differentiation vs single-mechanism products.

BERBERINE: 12+ published human RCTs on metabolic parameters. Key meta-analysis (Lan et al., 2015): significant effects on glucose metabolism markers. Mechanism: AMPK activation, PCSK9 downregulation. Dose range in literature: 500–1500 mg/day. Note: GeLiPthin-1 uses micronized form for enhanced absorption at lower total dose.

OLEOYLETHANOLAMIDE (OEA): Endogenous lipid mediator. Published human studies (Tutunchi et al., 2020) showing appetite modulation via PPARα/vagal pathway. Mechanism: PPARα activation → vagal afferent signalling → hypothalamic satiety centres. Naturally produced in the small intestine after fat consumption; supplementation provides consistent signalling independent of dietary fat intake.

SAFFRON EXTRACT: 3+ published RCTs specifically on appetite/snacking. Key study (Gout et al., 2010): significant reduction in snacking events vs placebo over 8 weeks. Mechanism: serotonergic modulation via crocin and safranal. Additional published evidence on mood support — relevant because stress-related eating is a major contributor to overconsumption.

EGCG (GREEN TEA): Extensive meta-analysis evidence. Hursel et al. (2009): catechin-caffeine mixtures increased energy expenditure by 4.7% (approximately 100 kcal/day). Mechanism: COMT inhibition → prolonged norepinephrine → increased thermogenesis. Also published evidence on fat oxidation enhancement.

CAPSAICIN/CAPSIATE: Published meta-analysis (Whiting et al., 2012): capsaicinoids increase energy expenditure by approximately 50 kcal/day. Capsiate provides equivalent thermogenic benefit without pungency or GI irritation. Mechanism: TRPV1 activation → sympathetic nervous system → brown adipose tissue thermogenesis.

BIFIDOBACTERIUM BREVE BBr60: Probiotic strain with published evidence on gut-brain axis modulation. Specific strain documentation showing viability through gastric transit, colonisation capacity, and influence on short-chain fatty acid production. Relevant to appetite regulation via the microbiome-gut-brain axis.

CHROMIUM PICOLINATE: EU-authorised health claim (Commission Regulation 432/2012): 'Chromium contributes to the maintenance of normal blood glucose levels.' Extensive published literature on insulin sensitivity support. The 180 µg dose provides 514% DV — well within safe upper limits.

Important: Each ingredient has individual published evidence. However, the complete GeLiPthin-1 formula has NOT been tested as a whole in a human clinical trial. The preclinical study (below) tested the complete formula in an animal model.

STUDY DESIGN: Preclinical study conducted by Prof. Dr. Oğuz Kul. Model: High-Fat Diet (HFD)-induced obesity in male Wistar Albino rats. Diet: 5 kcal/g, 60% fat for 8 weeks to induce obesity (baseline ~250g → ~420g). Intervention period: 6 weeks post-obesity induction.

GROUP ALLOCATION: Control (n=5) — normal rat diet. Obesity (n=8) — HFD only. Obesity + Probiotic/Prebiotic (n=8) — HFD + probiotic comparator. Obesity + GLP-1 Receptor Agonist (n=8) — HFD + pharmaceutical GLP-1 RA (positive control). Obesity + GeLiPthin-1 (n=8) — HFD + GeLiPthin-1 formula.

PRIMARY OUTCOME — BODY WEIGHT CHANGE (%): Obesity group: +4.2% (continued weight gain). Probiotic/Prebiotic: +3.1% (non-significant vs obesity). GLP-1 Receptor Agonist: −1.5% (non-significant vs obesity). GeLiPthin-1: −3.0% (p<0.05 vs obesity; p<0.05 vs probiotic).

STATISTICAL SIGNIFICANCE: Obesity vs GeLiPthin-1: p<0.05 (SIGNIFICANT). Probiotic vs GeLiPthin-1: p<0.05 (SIGNIFICANT). GeLiPthin-1 vs GLP-1 agonist: not significant (comparable efficacy). Obesity vs GLP-1 agonist: not significant. Obesity vs Probiotic: not significant.

SECONDARY OUTCOME — FEED CONSUMPTION: GeLiPthin-1 group showed significant reduction in feed consumption compared to obesity control, indicating genuine appetite suppression rather than merely metabolic effects.

CONCLUSIONS FROM INVESTIGATORS: (1) The animal model is translational to human obesity. (2) GLP-1 analogue and GeLiPthin-1 both achieved weight loss. (3) GeLiPthin-1 shows significant reduction in appetite and feed consumption. (4) GeLiPthin-1 achieved statistically significant weight loss comparable to a GLP-1 receptor agonist in this model.

CRITICAL CONTEXT FOR AFFILIATES: This is a PRECLINICAL study (animal model). It demonstrates proof-of-concept for the multi-pathway mechanism but does NOT constitute human clinical evidence. You may reference 'preclinical data showing weight management support' but NEVER claim 'clinically proven weight loss in humans' or compare directly to GLP-1 drugs like Ozempic/Wegovy.

APPROVED CLAIMS (safe to use): 'Supports healthy appetite regulation' | 'Designed to support metabolic wellness as part of a balanced lifestyle' | 'Contains ingredients that may help support satiety signalling' | 'Formulated with Micro Matrix Technology for enhanced delivery' | 'Contains chromium which contributes to normal macronutrient metabolism' | 'Multi-pathway approach to weight management support' | 'Contains clinically studied individual ingredients' | 'Preclinical research supports the multi-pathway mechanism'

PROHIBITED CLAIMS (never use): 'Works like Ozempic or any GLP-1 receptor agonist drug' | 'Raises GLP-1 levels' (only the drug does this directly) | 'Clinically proven to cause weight loss' (no human clinical trial on finished product) | 'Treats obesity or diabetes' | 'FDA approved' | 'Natural Ozempic alternative' | 'Guaranteed weight loss' | 'Burns fat' | 'Lose X pounds in Y weeks' | 'Doctor recommended' (unless a specific doctor endorses it)

NUANCED POSITIONING: You CAN say: 'GeLiPthin-1 targets multiple pathways involved in appetite regulation, including some of the same biological systems that pharmaceutical approaches target — but through nutritional, not pharmaceutical, mechanisms.' You CANNOT say: 'GeLiPthin-1 works like GLP-1 drugs' or 'natural version of Ozempic.'

SOCIAL MEDIA SPECIFIC: Never use before/after photos implying guaranteed results. Never use the word 'cure' or 'treat.' Never reference specific weight loss amounts. Always include the FDA disclaimer in any post making structure/function claims. Hashtags like #NaturalOzempic or #GLP1Alternative are PROHIBITED.

Key takeaway: GeLiPthin-1 has strong preclinical data and well-evidenced individual ingredients. Position it as a sophisticated multi-pathway formula for people who want nutritional support alongside healthy lifestyle choices — never as a drug replacement or guaranteed weight loss solution.

Required FDA Disclaimer: 'These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.'